Publications in collaboration with researchers from National Cheng Kung University Hospital (2)

2021

  1. Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC

    Journal of Thoracic Oncology

2020

  1. Long-term outcomes and retreatment among patients with previously treated, programmed death-ligand 1‒positive, advanced non‒small-cell lung cancer in the KEYNOTE-010 study

    Journal of Clinical Oncology, Vol. 38, Núm. 14, pp. 1580-1591